Laboratory diagnostics of patients with MGUS and results of their monitoring in a regional biochemical laboratory within 10 years
Authors:
L. Šolcová 1,3; J. Šimková 1; V. Maisnar 2
Authors‘ workplace:
Oddělení klinické biochemie, ON Trutnov a. s.
1; IV. interní hematologická klinika, FN a LF UK Hradec Králové
2; Ústav klinické biochemie a diagnostiky, Fakultní nemocnice Hradec Králové
3
Published in:
Klin. Biochem. Metab., 27, 2019, No. 3, p. 112-115
Overview
ted B-cells producing the monoclonal immunoglobulin (MIG). Monoclonal immunoglobulin (M - protein, M – component, paraprotein) consists of both an intact immunoglobulin molecule or also only of the structural component, i.e. light chain kappa or lambda, rarely heavy chain. The basic investigative methods of detection of the monoclonal immunoglobulin belong electrophoresis of serum protein and immunofixation electrophoresis including the determination of free light chains. Our report refers to the actual observation of MGUS (monoclonal gammopathies of uncertain significance) laboratory diagnosed in our regional laboratory and their development over 10 years.
Keywords:
free light chains – monoclonal gammopathy – monoclonal immunoglobulin – immunofixation electrophoresis – mo-noclonal gammopathy of undetermined significance (MGUS).
Sources
1. Landgren O., Kyle R. A., Rajkumar S. V. From mye-loma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res, 2011, 17(6), 2011, s. 1243-1252.
2. Landgren O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma:biological insights and early treatment strategies. Hematology, 2013, p. 478-487.
3. Maisnar V., Tichý M. a kol. Monoklonální imunoglobuliny – výskyt, význam a možnosti jejich průkazu. 1. vydání Nucleus HK, Praha 2012, 129 s.
4. Maisnar V. Riziko přechodu monoklonální gamapatie nejasného významu do maligní monoklonální gamapatie. Klin Biochem Metab, 2013, 21(2), s. 93-96.
5. Van den Donk N. W. C. J., Mutis T., Poddighe P. J., Lokhorst H. M., Zweegman S. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol, 2016, 38(Suppl.1), p. 110-122.
6. Kyle R. A., Rajkumar S. V. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006, 134, p. 573-589.
7. Landgren O., Kyle R. A., Pfeiffer R. M., Katzmann J. A., Caporaso N. E., Hayes R. B., Dispenzieri A., Kumar S., Clark R. J., Baris D., Hoover R., Rajkumar S. V. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 2009, p. 5412-17.
8. Tichý M. Laboratorní analýza monoklonálních imunoglobulinů Tichý M. Laboratorní analýza mono-klonálních imunoglobulinů (paraproteinů). 1. vydání Finidr, Český Těšín 1997, 96 s.
9. Tichý M., Vávrová J., Friedecký B., Maisnar V. Přehled metod na stanovení volných lehkých řetězců. Klin Biochem Metab, 2008, 16(37), s. 93-96.
10. Kyle R. A., Therneau T. M., Rajkumar S. V. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Eng J Med, 2002, 346(8), p.564-569.
11. Kyle R. A., Therneau T. M., Rajkumar S. V. et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc, 2004, 79(7), p.859-866.
12. Sandecká V. et al. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. Eur J Haematol. 2017; 99(1): 80-90.
13. Rajkumar S. V. Multiple myeloma:update on diagnosis, risk-stratification and management. Am J Hematol 2016; 91(7):19-34.
14. Kyle R. A., Rajkumar S. V., Therneau T. M. et al. Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance. Clinn Lymphoma, 2005, 5(4), p.257-260.
15. Hájek R., Maisnar V. et al. Diagnostika a léčba mnohočetného myelomu. Transfúze a hematologie dnes, 2018, Suppl, s.151-154.
16. Maisnar V. Nová diagnostická kritéria mnohočetného myelomu. Klin Biochem Metab, 2016, 24(45), s. 127-128.
17. Sandecká V., Pour L., Adam Z. et al. Monoklonální gamapatie nejasného významu. Klin Onkol, 2018, 31(4), s.270-276.
Labels
Clinical biochemistry Nuclear medicine Nutritive therapistArticle was published in
Clinical Biochemistry and Metabolism
2019 Issue 3
Most read in this issue
- XIV. celostátní sjezd České společnosti klinické biochemie
- Laboratory diagnostics of patients with MGUS and results of their monitoring in a regional biochemical laboratory within 10 years
- Harmonization in clinical laboratories. Concepts and problems. Metrological continuity, standardization, harmonization
- HPV related deregulation of selected microRNAs in sinonasal squamous cell carcinoma